Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Daniel A. Casciano is active.

Publication


Featured researches published by Daniel A. Casciano.


ACS Nano | 2010

Cytotoxicity Effects of Graphene and Single-Wall Carbon Nanotubes in Neural Phaeochromocytoma-Derived PC12 Cells

Yongbin Zhang; Syed F. Ali; Enkeleda Dervishi; Yang Xu; Zhongrui Li; Daniel A. Casciano; Alexandru S. Biris

Graphitic nanomaterials such as graphene layers (G) and single-wall carbon nanotubes (SWCNT) are potential candidates in a large number of biomedical applications. However, little is known about the effects of these nanomaterials on biological systems. Here we show that the shape of these materials is directly related to their induced cellular toxicity. Both G and SWCNT induce cytotoxic effects, and these effects are concentration- and shape-dependent. Interestingly, at low concentrations, G induced stronger metabolic activity than SWCNT, a trend that reversed at higher concentrations. Lactate dehydrogenase levels were found to be significantly higher for SWCNT as compared to the G samples. Moreover, reactive oxygen species were generated in a concentration- and time-dependent manner after exposure to G, indicating an oxidative stress mechanism. Furthermore, time-dependent caspase 3 activation after exposure to G (10 microg/mL) shows evidence of apoptosis. Altogether these studies suggest different biological activities of the graphitic nanomaterials, with the shape playing a primary role.


Mutation Research\/reviews in Genetic Toxicology | 1981

The use of Chinese hamster ovary cells to quantify specific locus mutation and to determine mutagenicity of chemicals: A report of the GENE-TOX program☆

Abraham Hsie; Daniel A. Casciano; D.B. Couch; D.F. Krahn; J.P. O'neill; B.L. Whitfield

Abstract The GENE-TOX Group on Specific Gene Mutations in Chinese Hamster Ovary (CHO) Cells has evaluated the use of mutational systems in these cells for identification of mutagenic chemicals from 261 references in the file of the Environmental Mutagen Information Center, Oak Ridge National Laboratory by February, 1979; 68 references were found to be relevant to the stated task. After establishing that the end-point of mutational measurement occurs at a specific locus and the determinations are quantifiable and reproducible, data from 21 references were found to fulfill such requirements. Among them, 14 were concerned with chemically-induced mutations to resistance to a purine analogue, 6-thioguanine, which selects for variants deficient in the enzyme hypoxanthine—guanine phosphoribosyl transferase (HGPRT). This mutational system is referred to as the CHO/HGPRT assay. Studies with other genetic markers offer promise for the development of quantitative specific genemutational assays, but these studies have not advanced thoroughly enough to assess their value. Several lines of genetic, physiological and biochemical evidence support the premise that the CHO/HGPRT system fulfills the criteria for measurement of specific gene mutations using CHO-K1-BH4 subclone and other appropriate CHO subclones. Based largely on published information, this Work Group has suggested a protocol for testing of chemical agents with consideration of the following: cells, media, culture conditions and their quality control, treatment with test compounds with and without an exogenous metabolic activation system, estimation of cytoxicity (cloning efficiency), optimum expression and selection of the mutant phenotype, calculation of mutation frequency, positive and negative controls, vehicles or solvents, spontaneous mutation frequency, dosage selection and number of doses, and collection of raw data. For interpretation of the mutagenesis data, this Work Group recommends various ways of presenting data, numerous criteria for acceptability of data, the need to use appropriate statistical procedures for data evaluation, and a potential applicability of results to hazard evaluation. Evaluation of test performances with 18 chemicals revealed that the correlation between mutagenicity in CHO/HGPRT assay and animal mutagenicity and carcinogenicity is high. Since the number of chemicals tested was small and 17 of the 18 compounds were direct-acting agents, the utility of the system for identification of various classes of potential mutagens and carcinogens cannot be adequately assessed until more chemical classes, especially promutagens, are tested. However, the assay has a sound genetic and biochemical basis for quantifying specific locus mutation reproducibly. The fact that CHO cells are also useful for determination of chemically-induced chromosome aberration and sister-chromatid exchange adds an additional strength to the assay. Future research should address the possible improvement of procedures for phenotypic expression and application for testing gaseous and volatile liquids, as well as such problems as appropriate metabolic activation system(s) and effective statistical procedures common to perhaps all short-term cellular assays. Recent rapid development of mutagen test systems like the CHO/HGPRT assay calls for a need to update and evaluate the data base generated.


Environmental and Molecular Mutagenesis | 2000

In vivo transgenic mutation assays.

John A. Heddle; Stephen Dean; Takehiko Nohmi; Michaël E.T.I. Boerrigter; Daniel A. Casciano; George R. Douglas; Barry W. Glickman; Nancy J. Gorelick; Jon C. Mirsalis; Hans-Jörg Martus; Thomas R. Skopek; Véronique Thybaud; Kenneth R. Tindall; Nobuhiro Yajima

Transgenic rodent gene mutation models provide quick and statistically reliable assays for mutations in the DNA from any tissue. For regulatory applications, assays should be based on neutral genes, be generally available in several laboratories, and be readily transferable. Five or fewer repeated treatments are inadequate to conclude that a compound is negative but more than 90 daily treatments may risk complications. A sampling time of 35 days is suitable for most tissues and chemicals, while shorter sampling times might be appropriate for highly proliferative tissues. For phage‐based assays, 5 to 10 animals per group should be analyzed, assuming a spontaneous mutant frequency (MF) of ∼3 × 10−5 mutants/locus and 125,000–300,000 plaque or colony forming units (PFU or CFU) per tissue. Data should be generated for two dose groups but three should be treated, at the maximum tolerated dose (MTD), two‐thirds the MTD, and one‐third the MTD. Concurrent positive control animals are only necessary during validation, but positive control DNA must be included in each plating. Tissues should be processed and analyzed in a block design and the total number of PFUs or CFUs and the MF for each tissue and animal reported. Sequencing data would not normally be required but might provide useful additional information in specific circumstances. Statistical tests used should consider the animal as the experimental unit. Nonparametric statistical tests are recommended. A positive result is a statistically significant dose‐response and/or statistically significant increase in any dose group compared to concurrent negative controls using an appropriate statistical model. A negative result is statistically nonsignificant with all mean MF within two standard deviations of the control. Environ. Mol. Mutagen. 35:253–259, 2000


Mutation Research\/genetic Toxicology | 1987

A protocol and guide for the in vitro rat hepatocyte DNA-repair assay.

Byron E. Butterworth; John Ashby; Edilberto Bermudez; Daniel A. Casciano; Jon C. Mirsalis; Gregory S. Probst

The in vitro rat-hepatocyte DNA-repair assay is a valuable tool in assessing the genotoxic activity of chemical agents. An advantage of the assay is that the target cells themselves are metabolically competent, so that the patterns of metabolic activation and detoxification closely reflect those in the whole animal. This article provides a typical procedure and guidelines for conducting the rat in vitro hepatocyte DNA-repair assay.


Mutation Research\/reviews in Genetic Toxicology | 1983

Unscheduled DNA synthesis tests: A report of the U.S. environmental protection agency gene-tox program☆

Ann D. Mitchell; Daniel A. Casciano; Martin L. Meltz; Douglas E. Robinson; Richard H. C. San; Elizabeth S. Von Halle

The utility of unscheduled DNA synthesis (UDS) testing for screening potentially hazardous chemicals was evaluated using the published papers and technical reports available to the UDS Work Group. A total of 244 documents were reviewed. Based on criteria defined in advance for evaluation of the results, 169 were rejected. From the 75 documents accepted, results were reviewed for 136 chemicals tested using autoradiographic approaches and for 147 chemicals tested using liquid scintillation counting (LSC) procedures; 38 chemicals were tested by both approaches to measure UDS. Since there were no documents available that provided detailed recommendations of UDS screening protocols or criteria for evaluating the results, the UDS Work Group presents suggested protocols and evaluation criteria suitable for measuring and evaluating UDS by autoradiography in primary rat hepatocytes and diploid human fibroblasts and by the LSC approach in diploid human fibroblasts. UDS detection is an appropriate system for inclusion in carcinogenicity and mutagenicity testing programs, because it measures the repair of DNA damage induced by many classes of chemicals over the entire mammalian genome. However, for this system to be utilized effectively, appropriate metabolic activation systems for autoradiographic measurements of UDS in human diploid fibroblasts must be developed, the nature of hepatocyte-to-hepatocyte variability in UDS responses must be determined, and the three suggested protocols must be thoroughly evaluated by using them to test a large number of coded chemicals of known in vivo mutagenicity and carcinogenicity.


Expert Review of Molecular Diagnostics | 2004

QA/QC: challenges and pitfalls facing the microarray community and regulatory agencies

Leming Shi; Weida Tong; Federico Goodsaid; Felix W. Frueh; Hong Fang; Tao Han; James C. Fuscoe; Daniel A. Casciano

The scientific community has been enthusiastic about DNA microarray technology for pharmacogenomic and toxicogenomic studies in the hope of advancing personalized medicine and drug development. The US Food and Drug Administration has been proactive in promoting the use of pharmacogenomic data in drug development and has issued a draft guidance for the pharmaceutical industry on data submissions. However, many challenges and pitfalls are facing the microarray community and regulatory agencies before microarray data can be reliably applied to support regulatory decision making. Four types of factors (i.e., technical, instrumental, computational and interpretative) affect the outcome of a microarray study, and a major concern about microarray studies has been the lack of reproducibility and accuracy. Intralaboratory data consistency is the foundation of reliable knowledge extraction and meaningful crosslaboratory or crossplatform comparisons; unfortunately, it has not been seriously evaluated and demonstrated in every study. Profound problems in data quality have been observed from analyzing published data sets, and many laboratories have been struggling with technical troubleshooting rather than generating reliable data of scientific significance. The microarray community and regulatory agencies must work together to establish a set of consensus quality assurance and quality control criteria for assessing and ensuring data quality, to identify critical factors affecting data quality, and to optimize and standardize microarray procedures so that biologic interpretation and decision-making are not based on unreliable data. These fundamental issues must be adequately addressed before microarray technology can be transformed from a research tool to clinical practices.


Journal of Applied Toxicology | 2010

Cytotoxicity and biological effects of functional nanomaterials delivered to various cell lines.

Meena Mahmood; Daniel A. Casciano; Teodora Mocan; Cornel Iancu; Yang Xu; Lucian Mocan; Dana Iancu; Enkeleda Dervishi; Zhongrui Li; Mustafa Z. Abdalmuhsen; Alexandru R. Biris; Nawab Ali; Paul C. Howard; Alexandru S. Biris

Functional nanomaterials that included gold, silver nanoparticles and single wall carbon nanotubes were delivered to two cell lines (MLO‐Y4 osteocytic cells and HeLa cervical cancer cells) in various concentrations. The cells were found to uptake the nanomaterials in a relatively short time, a process that significantly affected the shape and the size of the cells. The percentage of cellular death, due to the delivery of these nanomaterials, was found to be the highest for carbon nanotubes and increased gradually with the concentration of these nanostructures. Moreover, when the nanomaterials were delivered to the cells combined with commonly used chemotherapeutic agents such as etoposide or dexamethasone, the number of the cells that died increased significantly (100–300%) as compared with the case when only the nanomaterials or the chemotherapeutic agents were delivered. The experimental results were confirmed by Caspase 3 studies, indicating a strong interaction between the nanomaterials used in this study and the protein structure of the cells, which allowed a more effective action of the apoptotic agents. These findings could be the foundation of a new class of cancer therapies that are composed of both chemotherapeutic agents and nanomaterials. Copyright


Critical Reviews in Toxicology | 2009

Creating context for the use of DNA adduct data in cancer risk assessment: I. Data organization.

Annie M. Jarabek; Lynn H. Pottenger; Larry S. Andrews; Daniel A. Casciano; Michelle R. Embry; James H. Kim; R. Julian Preston; M. Vijayaraj Reddy; Rita Schoeny; David E. G. Shuker; Julie A. Skare; James A. Swenberg; Gary M. Williams; Errol Zeiger

The assessment of human cancer risk from chemical exposure requires the integration of diverse types of data. Such data involve effects at the cell and tissue levels. This report focuses on the specific utility of one type of data, namely DNA adducts. Emphasis is placed on the appreciation that such DNA adduct data cannot be used in isolation in the risk assessment process but must be used in an integrated fashion with other information. As emerging technologies provide even more sensitive quantitative measurements of DNA adducts, integration that establishes links between DNA adducts and accepted outcome measures becomes critical for risk assessment. The present report proposes an organizational approach for the assessment of DNA adduct data (e.g., type of adduct, frequency, persistence, type of repair process) in concert with other relevant data, such as dosimetry, toxicity, mutagenicity, genotoxicity, and tumor incidence, to inform characterization of the mode of action. DNA adducts are considered biomarkers of exposure, whereas gene mutations and chromosomal alterations are often biomarkers of early biological effects and also can be bioindicators of the carcinogenic process.


Mutation Research | 1983

Correlation between specific DNA-methylation products and mutation induction at the HGPRT locus in Chinese hamster ovary cells

David T. Beranek; Robert H. Heflich; Ralph L. Kodell; Suzanne M. Morris; Daniel A. Casciano

Suspension cultures of Chinese hamster ovary (CHO) cells were exposed to methyl methanesulfonate (MMS) or methylnitrosourea (MNU) and assayed for mutation induction (6-thioguanine resistance) and for specific DNA adducts. DNA methylation at the 1-, 3- and 7-positions of adenine, the 3-, O6- and 7-positions of guanine, and phosphate was detected in cultures exposed to MMS, while MNU produced 3- and 7-methyladenine, 3-methylcytosine, 3-, O6- and 7-methylguanine, O4-methylthymidine and methylated phosphodiesters. When mutations induced by MMS and MNU were compared by linear correlation analysis with levels of each of these adducts, only O6-methylguanine displayed a strong correlation with mutations (r = 0.879, p less than 0.001). The relationship between O6-methylguanine and induced mutations in CHO cells is similar to that previously reported in CHO cells for O6-ethylguanine and mutations (Heflich et al., 1982) and indicates that alkylation-induced mutations at the HGPRT locus in CHO cells are primarily associated with O6-alkylguanine formation.


Biochemical and Biophysical Research Communications | 1982

Metabolism of the mutagenic environmental pollutant, 6-nitrobenzo[a]pyrene: Metabolic activation via ring oxidation

Peter P. Fu; Ming W. Chou; Shen K. Yang; Frederick A. Beland; Fred F. Kadlubar; Daniel A. Casciano; Robert H. Heflich; Frederick E. Evans

Abstract Metabolism of 6-nitrobenzo[a]pyrene by rat liver microsomes yielded 1- and 3-hydroxy-6-nitrobenzo[a]pyrene, 6-nitrobenzo[a]pyrene-1,9- and -3,9-hydroquinone and benzo[a]pyrene-3,6-quinone. The monohydroxylated metabolites were more mutagenic than 6-nitrobenzo[a]pyrene in a Salmonella typhimurium / microsome reversion assay. These results indicate that ring hydroxylation is involved in the metabolic activation of this nitro-polycyclic aromatic hydrocarbon.

Collaboration


Dive into the Daniel A. Casciano's collaboration.

Top Co-Authors

Avatar

Anane Aidoo

National Center for Toxicological Research

View shared research outputs
Top Co-Authors

Avatar

Ritchie J. Feuers

National Center for Toxicological Research

View shared research outputs
Top Co-Authors

Avatar

Robert H. Heflich

National Center for Toxicological Research

View shared research outputs
Top Co-Authors

Avatar

Suzanne M. Morris

National Center for Toxicological Research

View shared research outputs
Top Co-Authors

Avatar

Joseph G. Shaddock

National Center for Toxicological Research

View shared research outputs
Top Co-Authors

Avatar

Lascelles E. Lyn-Cook

National Center for Toxicological Research

View shared research outputs
Top Co-Authors

Avatar

James L. Pipkin

National Center for Toxicological Research

View shared research outputs
Top Co-Authors

Avatar

William G. Hinson

National Center for Toxicological Research

View shared research outputs
Top Co-Authors

Avatar

Alexandru S. Biris

University of Arkansas at Little Rock

View shared research outputs
Top Co-Authors

Avatar

Lynda J. McGarrity

National Center for Toxicological Research

View shared research outputs
Researchain Logo
Decentralizing Knowledge